Literature DB >> 2749109

Clinical features of Lassa fever in Liberia.

J D Frame1.   

Abstract

Two hundred thirteen cases of Lassa fever (LF) were diagnosed by virus isolation and seroconversion at Curran Lutheran Hospital in Zorzor, Liberia, between July 1980 and April 1986. An additional 40 cases of probable and presumptive LF were diagnosed on the basis of single serum samples. Of the 246 assessable patients, 23 (9%) died; no data were available for seven patients. Five (16%) of 32 pregnant women and three (43%) of seven immediately postpartum women died. Four (26%) of 15 children less than 12 years died. Case-fatality rates among 125 nonpregnant women and 67 men were approximately 6%. Among 150 patients studied in detail, the case-fatality rate was also 9%. Seventeen (11%) of these patients had abnormal bleeding; of these, six (35%) died. Most platelet counts were at low normal to mildly depressed levels. However, serial counts in seven patients suggested a decrease on about days 10-12 of illness. The symptoms of LF in Liberia are those of a viral syndrome. Edema, sometimes marked, is noted in seriously ill patients. A great variation in mortality and incidence of abnormal bleeding is recorded in reported series of LF; it appears that hemorrhage is a marker for cases with a high mortality. The incidence and severity of hearing defects in LF outbreaks vary. Elucidation of a number of clinical problems in LF requires more information on how strain differences affect the pattern of illness.

Entities:  

Mesh:

Year:  1989        PMID: 2749109     DOI: 10.1093/clinids/11.supplement_4.s783

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  23 in total

1.  Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.

Authors:  D G Bausch; P E Rollin; A H Demby; M Coulibaly; J Kanu; A S Conteh; K D Wagoner; L K McMullan; M D Bowen; C J Peters; T G Ksiazek
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.

Authors:  David Safronetz; James E Strong; Friederike Feldmann; Elaine Haddock; Nafomon Sogoba; Douglas Brining; Thomas W Geisbert; Dana P Scott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

Review 3.  Immunobiology of Ebola and Lassa virus infections.

Authors:  Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best
Journal:  Nat Rev Immunol       Date:  2017-01-23       Impact factor: 53.106

4.  Pre-clinical development of a vaccine against Lassa fever.

Authors:  L Banadyga; D R Stein; X Qiu; D Safronetz
Journal:  Can Commun Dis Rep       Date:  2018-06-07

Review 5.  Dengue virus pathogenesis: an integrated view.

Authors:  Byron E E Martina; Penelope Koraka; Albert D M E Osterhaus
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

6.  Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation.

Authors:  Danny A Asogun; Donatus I Adomeh; Jacqueline Ehimuan; Ikponmwonsa Odia; Meike Hass; Martin Gabriel; Stephan Olschläger; Beate Becker-Ziaja; Onikepe Folarin; Eric Phelan; Philomena E Ehiane; Veritas E Ifeh; Eghosasere A Uyigue; Yemisi T Oladapo; Ekene B Muoebonam; Osagie Osunde; Andrew Dongo; Peter O Okokhere; Sylvanus A Okogbenin; Mojeed Momoh; Sylvester O Alikah; Odigie C Akhuemokhan; Peter Imomeh; Maxy A C Odike; Stephen Gire; Kristian Andersen; Pardis C Sabeti; Christian T Happi; George O Akpede; Stephan Günther
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

7.  Safe IV opioid titration in patients with severe acute pain.

Authors:  Chris Pasero
Journal:  J Perianesth Nurs       Date:  2010-10       Impact factor: 1.084

8.  Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Authors:  Kathleen A Cashman; Mark A Smith; Nancy A Twenhafel; Ryan A Larson; Kevin F Jones; Robert D Allen; Dongcheng Dai; Jarasvech Chinsangaram; Tove' C Bolken; Dennis E Hruby; Sean M Amberg; Lisa E Hensley; Mary C Guttieri
Journal:  Antiviral Res       Date:  2011-03-01       Impact factor: 5.970

9.  A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.

Authors:  David Safronetz; Chad Mire; Kyle Rosenke; Friederike Feldmann; Elaine Haddock; Thomas Geisbert; Heinz Feldmann
Journal:  PLoS Negl Trop Dis       Date:  2015-04-17

10.  The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection.

Authors:  Titus S Ibekwe; Maxwell M Nwegbu; Daniel Asogun; Donatus I Adomeh; Peter O Okokhere
Journal:  Niger Med J       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.